Allergan Breast Implants
Allergan Breast Implants
If you received textured or smooth implants manufactured by Allergan, you may be affected by this class action lawsuit. Please fill out the form below to get in touch with us. Joining our contact list creates no financial obligation and we will keep all the information that you provide to us confidential.
Current Status: The Certification Hearing in this matter is schedule for September 28, 2022, for 3 days.
|Case Name:||Bunsko v. Allergan Inc., SCBC No. 196308, Vancouver Registry (the “BC Allergan Class Action”)|
|Kibalian v. Allergan PLC, CV-19-00620507-00CP (“the ON Allergan Class Action”)|
|Basal v. Allergan Inc., No: 500-06-000966-198 (“the QC Allergan Class Action”)|
|Together the BC Allergan Class Action, the ON Allergan Class Action, the QC Allergan Class Action will be called “the National Allergan Class Actions”|
|Court:||The BC Allergan Class Action was filed in the Supreme Court of British Columbia|
|Date Filed:||The BC Allergan Class Action was filed May 31, 2019.|
|Class Members:||Collectively the class has been defined as “All persons residing in Canada who were implanted with breast implants manufactured and distributed by Allergan plc and several of its affiliates”.|
This proposed class action arises from Allergan’s alleged failure to disclose health risks associated with their breast implants, sold in Canada, including in British Columbia. Class action lawsuits were commenced in British Columbia, Ontario, and Quebec, collectively the National Allergan Class Actions.
Health Canada has recently suspended Allergan’s license for its Biocell breast implants. The full details of the Health Canada recall can be found here.
Our firm is seeking compensation for persons who underwent implant surgery with Allergan breast implants without being provided with full and adequate disclosure of the risks associated with the implants, including the risk of Anaplastic Large Cell Lymphoma (“BIA-ALCL”) and for related financial losses associated with these health issues.
A certification hearing has been scheduled in the ON Action for Dec 1-3, 2021.
Consortium including RHE Lawyers obtain certification of issues relating to Anaplastic Large Cell Lymphoma and Allergan breast implants
On March 23, 2022, Justice Morgan of the Ontario Superior Court of Justice granted certification of common issues relating to the propensity of Allergan Biocell® implants to cause Anaplastic Large Cell Lymphoma (“ALCL”). This means that the issues relating to ALCL are authorized to proceed to a common issues trial. The reasons for judgment of Justice Morgan and the entered order for certification can be found here.
The Plaintiffs also intend to seek certification of additional issues relating to all silicone breast implants manufactured and sold in Canada by Allergan since 1999, due to their propensity to cause autoimmune disease (sometimes termed “ASIA” or “BII”) and premature rupture. The certification hearing of those issues will proceed in the Ontario Superior Court of Justice on September 28-30, 2022.
If you have developed ALCL due to your Allergan breast implants, we encourage you to contact Ying Lee, Senior Paralegal, at firstname.lastname@example.org . We will provide updates on our website as the matter progresses and will also be offering a town hall Q&A meeting for class members in advance of the continuation of the certification hearing in September to provide further information.
Note: You are not obliged to fill in this form to participate in this class action. If you choose to do so, you are not retaining RHE LLP to act on your behalf. Providing the information requested does not make you a client of RHE LLP. All information submitted will be treated as confidential and will only be released as required by law or as you may consent.
I provide my consent and agree herein to receive communications from RHE LLP, which may include announcements regarding class actions, practice updates, newsletters, publications, event invitations or other information that may be of interest. I understand that consent to receive these electronic communications may be withdrawn at any time by emailing email@example.com.